Biopharmaceutical Firm Precigen Sees Stock Soar 58.92%
Shares in biopharmaceutical company Precigen surged 58.92% after the US Food and Drug Administration gave its approval to Papzimeos, a treatment for recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) infection. RRP can lead to severe symptoms such as voice disturbance and airway compromise, with no current cure. The condition affects … Read more